Price
$42.75
Increased by +1.38%
Dollar volume (20D)
90.74 M
ADR%
3.29
Earnings report date
Oct 30, 2025
Shares float
157.97 M
Shares short
10.79 M [6.83%]
Shares outstanding
159.39 M
Market cap
6.72 B
Beta
0.25
Price/earnings
N/A
20D range
40.03 44.99
50D range
34.84 45.66
200D range
23.95 45.66

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.

The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA).

It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy.

It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); Donidalorsen for patients with hereditary angioedema; and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 that has completed Phase 2 clinical trial for the potential treatment of AS, a rare genetic neurological disease.

In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines.

It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi.

The company was incorporated in 1989 and is headquartered in Carlsbad, California.

Reported date EPSChange YoY EstimateSurprise
Jul 30, 25 0.70
Increased by +255.56%
-0.24
Increased by +391.67%
May 5, 25 -0.92
Increased by +5.66%
-1.01
Increased by +8.47%
Feb 19, 25 -0.43
Decreased by -617.33%
-0.84
Increased by +49.03%
Nov 6, 24 -0.95
Increased by +7.77%
-1.16
Increased by +18.10%
Aug 1, 24 -0.45
Increased by +25.00%
-0.92
Increased by +51.09%
May 7, 24 -0.98
Decreased by -12.64%
-1.05
Increased by +6.67%
Feb 21, 24 -0.06
Increased by +95.59%
-0.83
Increased by +92.77%
Nov 2, 23 -1.03
Decreased by -212.12%
-1.04
Increased by +0.96%
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 25 452.05 M
Increased by +100.69%
123.55 M
Increased by +286.45%
Increased by +27.33%
Increased by +192.91%
Mar 31, 25 131.61 M
Increased by +10.14%
-146.94 M
Decreased by -2.90%
Decreased by -111.64%
Increased by +6.58%
Dec 31, 24 226.58 M
Decreased by -30.18%
-104.35 M
Decreased by -1.03 K%
Decreased by -46.05%
Decreased by -1.51 K%
Sep 30, 24 134.00 M
Decreased by -6.94%
-140.48 M
Increased by +4.44%
Decreased by -104.84%
Decreased by -2.70%
Jun 30, 24 225.25 M
Increased by +19.81%
-66.27 M
Increased by +22.04%
Decreased by -29.42%
Increased by +34.93%
Mar 31, 24 119.50 M
Decreased by -8.78%
-142.80 M
Decreased by -15.16%
Decreased by -119.50%
Decreased by -26.25%
Dec 31, 23 324.50 M
Increased by +113.49%
-9.26 M
Increased by +82.19%
Decreased by -2.85%
Increased by +91.66%
Sep 30, 23 144.00 M
Decreased by -9.87%
-147.00 M
Decreased by -212.82%
Decreased by -102.08%
Decreased by -247.07%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY